Volume Alert - ARWR 6.54 Arrowhead Research Corp $
Post# of 78
ARWR Recent Posts: http://investorshangout.com/Arrowhead-Researc...RWR-53380/
ARWR Arrowhead Research Corp Recent Headline News
ARWR INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014 -- ARWR
GlobeNewswire - 2 hrs 29 mins ago
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp. ("Arrowhead Research" or the "Company" (Nasdaq:ARWR) stock between August 12, 2014 and October 8, 2014.
ARWR: 6.57 (+0.07)
Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD The Liver Meeting(R) 2014
Business Wire - Mon Nov 10, 8:15AM CST
--- Repeat dosing of ARC-AAT in primates shows reduction of approximately 90% of serum alpha 1 antitrypsin (AAT) with long duration of effect suggesting that monthly or less frequent dosing may be sufficient for sustained suppression of hepatic AAT production
ARWR: 6.57 (+0.07)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Research Corporation and Certain Officers - ARWR
PR Newswire - Fri Nov 07, 2:18PM CST
Pomerantz LLP has filed a class action lawsuit against Arrowhead Research Corporation ("Arrowhead" or the "Company" (NASDAQ: ARWR) and certain of its officers. The class action, filed in United States District Court, Central District of California, and docketed under 14-cv-07911, is on behalf of a class consisting of all persons or entities who purchased Arrowhead securities between August 12, 2014 and October 8, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
ARWR: 6.57 (+0.07)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Arrowhead Research Corp. to Contact Brower Piven Before the December 9, 2014 Lead Plaintiff Deadline in Class Action Lawsuit --- ARWR
GlobeNewswire - Thu Nov 06, 11:32AM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Arrowhead Research Corp. ("Arrowhead" or the "Company" (Nasdaq:ARWR) common stock during the period between August 12, 2014 and October 8, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 9, 2014 to seek appointment as lead plaintiff.
ARWR: 6.57 (+0.07)
Shares of ARWR Down 50.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:58AM CST
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on October 7th, 2014 at $13.00. In approximately 4 weeks, Arrowhead Research has returned 50.77% as of today's recent price of $6.40.
ARWR: 6.57 (+0.07)
Morning Briefing on Biotech Stocks - Arrowhead Research, Array BioPharma, Aegerion Pharma, Hemispherx Biopharma, and Aeterna Zentaris
PR Newswire - Wed Nov 05, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Arrowhead Research Corporation (NASDAQ: ARWR), Array BioPharma Inc. (NASDAQ: ARRY), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 4, 2014, the NASDAQ Composite ended at 4,623.64, down 0.33%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 17,383.84, and the S&P 500 closed at 2,012.10, down 0.28%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index also advancing 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
ARWR: 6.57 (+0.07), HEB: 0.28 (-0.01), AEZS: 0.61 (+0.03), AEGR: 21.44 (-0.12), ARRY: 3.81 (-0.03)
Hagens Berman Announces the Filing of a Class Action Lawsuit Against Arrowhead Research Corporation, Inc. (NASDAQ: ARWR)
GlobeNewswire - Tue Nov 04, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Arrowhead Research Corporation (Nasdaq:ARWR) ("Arrowhead" or "the Company" . The suit is pending in U.S. District Court for the Central District of California and investors have until December 9, 2014 to move for lead plaintiff.
ARWR: 6.57 (+0.07)
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
PropThink - Seeking Alpha - Mon Nov 03, 2:53PM CST
By Dr. Paul Nunzio De Santis and Jake King GlobeImmune (NASDAQ: GBIM ) IPO'd in June to little fanfare and has underperformed the biotech sector considerably since. Now, however, this overlooked stock is trading at all-time lows and only...
1 Comment
GBIM: 6.45 (-0.05), ALNY: 100.07 (+1.60), GILD: 107.16 (-0.85), ARWR: 6.57 (+0.07), CELG: 107.99 (+0.14)
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Arrowhead Research Corp.
GlobeNewswire - Mon Nov 03, 8:37AM CST
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Arrowhead Research Corporation ("Arrowhead" or the "Company" and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
ARWR: 6.57 (+0.07)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.16 (-0.85), CLVS: 58.72 (-2.59), ARWR: 6.57 (+0.07), ACHN: 14.44 (+1.96), MRK: 59.16 (-0.21), RTRX: 11.42 (+0.06), RGLS: 19.77 (-0.70), EPZM: 23.88 (-0.38), AGIO: 87.16 (+5.25), RMTI: 11.29 (+0.14), ARNA: 4.69 (+0.20), KERX: 15.45 (-0.49)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Arrowhead Research Corp. (ARWR) to Contact the Firm
GlobeNewswire - Fri Oct 31, 7:38PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Arrowhead Research Corp.("Arrowhead" or the "Company" (Nasdaq:ARWR) of the December 9, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Arrowhead and certain executives.
ARWR: 6.57 (+0.07)
47.8% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Oct 29, 9:36AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on October 7th, 2014 at $13.00. In approximately 3 weeks, Arrowhead Research has returned 47.85% as of today's recent price of $6.78.
ARWR: 6.57 (+0.07)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Oct 27, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
ARWR: 6.57 (+0.07), WG: 5.27 (+0.02), RTRX: 11.42 (+0.06), PENX: 18.83 (+0.02), BBLU: 1.30 (-0.07), CNL: 53.39 (-0.18)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Arrowhead Research Corporation of Class Action Lawsuit and Upcoming Deadline -- ARWR
GlobeNewswire - Mon Oct 27, 6:00AM CDT
Pomerantz LLP has filed a class action lawsuit against Arrowhead Research Corporation ("Arrowhead" or the "Company" (Nasdaq:ARWR) and certain of its officers. The class action, filed in United States District Court, Central District of California, and docketed under 14-cv-07911, is on behalf of a class consisting of all persons or entities who purchased Arrowhead securities between August 12, 2014 and October 8, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
ARWR: 6.57 (+0.07)
EQUITY ALERT: Rosen Law Firm Reminds Arrowhead Research Corp. Investors of Important Deadline in Class Action Filed by Firm - ARWR
GlobeNewswire - Fri Oct 24, 2:23PM CDT
Rosen Law Firm reminds purchasers of Arrowhead Research Corp. common stock (Nasdaq:ARWR) during the period between August 12, 2014 and October 8, 2014 of the important December 9, 2014 lead plaintiff deadline in the class action filed by the firm.
ARWR: 6.57 (+0.07)
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against Arrowhead Research Corporation -- ARWR
GlobeNewswire - Thu Oct 23, 9:04AM CDT
Morgan & Morgan announces that a securities class action has been commenced in the United States District Court for the Central District of California on behalf of purchasers of common stock of Arrowhead Research Corporation ("Arrowhead" (Nasdaq:ARWR) during the period of August 12, 2014 through October 8, 2014, inclusive (the "Class Period" .
ARWR: 6.57 (+0.07)
Nanotechnology - 2014 Global Strategic Business Report
M2 - Thu Oct 23, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6n85z6/nanotechnology) has announced the addition of the "Nanotechnology - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 411 companies including many key and niche players. This report analyzes the worldwide markets for Nanotechnology in US$ Billion by the following End-Use Sectors: - Chemicals - Automotive - Aerospace & Defense - Semiconductors & Electronics - Pharma & Healthcare - Food - Others Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Review Of Select Nanotechnology Based Product Markets 3. R&D Structure & Financing 4. Nanotech Patents - An Overview 5. Technology Overview 6. Techniques And Technologies 7. Nanotech Fears - Are They Justified? 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 411 (including Divisions/Subsidiaries - 424) - The United States (208) - Canada (11) - Japan (37) - Europe (131) - - France (7) - - Germany (54) - - The United Kingdom (28) - - Italy (3) - - Spain (1) - - Rest of Europe (38) - Asia-Pacific (Excluding Japan) (29) - Middle East ( Companies Mentioned - Advanced Diamond Technologies, Inc. - Advanced Nano Products Co., Limited - Altair Nanotechnologies Inc. - Arrowhead Research Corporation - Bruker Corporation - Catalytic Materials, LLC - Chemat Technology Inc. - eSpin Technologies, Inc. - ELITech Group - Genefluidics, Inc., - Hanwha Nanotech Corporation - Hybrid Plastics - Hyperion Catalysis International, Inc. - Integran Technologies, Inc. - Intrinsiq Materials Limited - Life Technologies Corporation - Luxtera, Inc. - Nanocyl S.A. - NanoMaterials Ltd, - Nanosys, Inc. - QuantumSphere, Inc. - Raymor Industries, Inc. - Rogue Valley Microdevices, Inc. - Shenzhen Nanotech Port Co., Ltd. - SouthWest NanoTechnologies, Inc. - Starpharma Holdings - Teledyne Scientific & Imaging, LLC - Unidym, Inc. For more information visit http://www.researchandmarkets.com/research/6n...technology
ARWR: 6.57 (+0.07)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Oct 22, 2:52PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Arrowhead Research Corp. ("Arrowhead" or the "Company" (Nasdaq: ARWR) common stock during the period between August 12, 2014 and October 8, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 9, 2014 to seek appointment as lead plaintiff.
ARWR: 6.57 (+0.07)
Downtrend Call Working As Arrowhead Research Stock Falls 48.0% (ARWR)
Comtex SmarTrend(R) - Wed Oct 22, 9:09AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on October 7th, 2014 at $13.00. In approximately 2 weeks, Arrowhead Research has returned 48.00% as of today's recent price of $6.76.
ARWR: 6.57 (+0.07)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014 -- ARWR
GlobeNewswire - Mon Oct 20, 11:40AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp. ("Arrowhead Research" or the "Company" (Nasdaq:ARWR) stock between August 12, 2014 and October 8, 2014.
ARWR: 6.57 (+0.07)